--- title: "WW International Adds Lilly's GLP-1 Foundayo To Med+ Program" type: "News" locale: "en" url: "https://longbridge.com/en/news/282207321.md" description: "WW International, Inc. has announced the addition of Eli Lilly's newly approved oral GLP-1 drug, Foundayo, to its Med+ program. This initiative aims to provide expanded treatment options for individuals with obesity or overweight. Eligible members can access this once-daily therapy, along with support from certified clinicians and the GLP-1 Success program. Pricing for self-pay patients starts at $149 per month, varying by dosage. Scott Honken, Chief Commercial Officer, emphasized the importance of this new offering in providing clinical support and guidance for members." datetime: "2026-04-09T13:42:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282207321.md) - [en](https://longbridge.com/en/news/282207321.md) - [zh-HK](https://longbridge.com/zh-HK/news/282207321.md) --- # WW International Adds Lilly's GLP-1 Foundayo To Med+ Program Add as your preferred news source on Google Add Now WW International, Inc. (WW), a weight loss solutions provider, on Thursday said it is now offering access to Eli Lilly and Company's newly approved oral GLP-1 drug Foundayo through its Med+ program and affiliated medical groups, expanding treatment options for people with obesity or overweight. The company said eligible members can access the once-daily, injection-free therapy alongside support from board-certified clinicians, insurance assistance and its GLP-1 Success program, which provides guidance before, during and after treatment. WW International added that pricing for self-pay patients will start at $149 per month for the lowest dose, with costs varying by dosage. "With this new offering, Weight Watchers is expanding access to a new FDA-approved option through a trusted platform built to help members access treatment with clinical support and ongoing guidance," said Scott Honken, Chief Commercial Officer at Weight Watchers. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md) - [WW.US](https://longbridge.com/en/quote/WW.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [WGHTQ.US](https://longbridge.com/en/quote/WGHTQ.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) ## Related News & Research - [GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?](https://longbridge.com/en/news/284837521.md) - [12:27 ETFuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment](https://longbridge.com/en/news/284423387.md) - [More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says](https://longbridge.com/en/news/284772786.md) - [WW International Announces Term Loan Prepayment and Deleveraging Plan](https://longbridge.com/en/news/284212388.md) - [BUZZ-Street View: Lilly's obesity play is evolving into a long game](https://longbridge.com/en/news/284898916.md)